X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (116) 116
humans (110) 110
oncology (108) 108
female (81) 81
male (70) 70
crizotinib (63) 63
aged (61) 61
respiratory system (60) 60
middle aged (59) 59
carcinoma, non-small-cell lung - drug therapy (58) 58
lung neoplasms - drug therapy (55) 55
adult (53) 53
lung neoplasms - pathology (51) 51
lung neoplasms - genetics (50) 50
carcinoma, non-small-cell lung - genetics (46) 46
carcinoma, non-small-cell lung - pathology (45) 45
protein kinase inhibitors - therapeutic use (45) 45
mutation (41) 41
chemotherapy (34) 34
aged, 80 and over (31) 31
lung cancer (30) 30
adenocarcinoma (27) 27
open-label (27) 27
lung cancer, non-small cell (26) 26
cell lung-cancer (25) 25
neoplasm staging (25) 25
pyridines - therapeutic use (25) 25
prognosis (24) 24
pyrazoles - therapeutic use (24) 24
alectinib (23) 23
antineoplastic agents - therapeutic use (23) 23
gefitinib (21) 21
hematology, oncology and palliative medicine (21) 21
receptor protein-tyrosine kinases - genetics (21) 21
resistance (20) 20
gene rearrangement (19) 19
non-small cell lung cancer (19) 19
retrospective studies (19) 19
treatment outcome (18) 18
alk (17) 17
anaplastic lymphoma kinase (17) 17
pulmonary/respiratory (17) 17
drug resistance, neoplasm - genetics (16) 16
metastasis (16) 16
cancer (15) 15
ceritinib (15) 15
genetic aspects (15) 15
mutations (15) 15
young adult (15) 15
acquired-resistance (14) 14
nsclc (14) 14
receptor, epidermal growth factor - genetics (14) 14
lung neoplasms - mortality (13) 13
medical colleges (13) 13
protein kinase inhibitors - pharmacology (13) 13
survival (13) 13
carbazoles - therapeutic use (12) 12
lung neoplasms - diagnosis (12) 12
molecular targeted therapy (12) 12
piperidines - therapeutic use (12) 12
receptor protein-tyrosine kinases - antagonists & inhibitors (12) 12
research (12) 12
adenocarcinoma - genetics (11) 11
carcinoma, non-small-cell lung - enzymology (11) 11
carcinoma, non-small-cell lung - mortality (11) 11
disease progression (11) 11
erlotinib (11) 11
gene (11) 11
lung neoplasms - enzymology (11) 11
patients (11) 11
proto-oncogene proteins c-met - genetics (11) 11
respiratory tract diseases (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
lung neoplasms - therapy (10) 10
non-small cell lung carcinoma (10) 10
protein kinase inhibitors - adverse effects (10) 10
survival rate (10) 10
tyrosine (10) 10
adenocarcinoma - pathology (9) 9
adolescent (9) 9
c-met (9) 9
california cancer registry (9) 9
egfr (9) 9
inhibitors (9) 9
lymphomas (9) 9
non-small-cell lung cancer (9) 9
oncogene proteins, fusion - genetics (9) 9
proto-oncogene proteins - genetics (9) 9
animals (8) 8
antineoplastic agents - adverse effects (8) 8
carcinoma, non-small-cell lung - diagnosis (8) 8
comprehensive genomic profiling (8) 8
diagnosis (8) 8
drug resistance, neoplasm (8) 8
epidemiology (8) 8
fusion (8) 8
gene expression profiling (8) 8
hemic and lymphatic diseases (8) 8
immunohistochemistry (8) 8
in situ hybridization, fluorescence (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2011, Volume 5, pp. 471 - 485
Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US.... 
Crizotinib | PF-02341066 | Non-small cell lung cancer | Anaplastic lymphoma kinase (ALK) | Rearrangement | non-small cell lung cancer | GEFITINIB | CHEMISTRY, MEDICINAL | FUSION | anaplastic lymphoma kinase (ALK) | OPEN-LABEL | ALK INHIBITOR | CHEMOTHERAPY | crizotinib | GENE | RESISTANCE | PHARMACOLOGY & PHARMACY | NEVER-SMOKERS | MUTATIONS | CLINICAL-RESPONSE | rearrangement | Gene Rearrangement - drug effects | Receptor, Epidermal Growth Factor - genetics | Pyrazoles - therapeutic use | Pyridines - chemistry | Humans | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Clinical Trials, Phase III as Topic | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic
Journal Article
The Oncologist, ISSN 1083-7159, 11/2012, Volume 17, Issue 11, pp. 1351 - 1375
Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anaplastic lymphoma kinase (ALK)‐rearranged... 
Crizotinib | ROS1 inhibitor | Chromosomal rearrangements | ALK inhibitor | Receptor tyrosine kinase fusion positive malignancies | Non‐small cell lung cancer (NSCLC) | MET inhibitor | Non-small cell lung cancer (NSCLC) | EML4-ALK FUSION GENE | C-MET RECEPTOR | IN-SITU-HYBRIDIZATION | EGFR MUTATION | OPEN-LABEL | ANAPLASTIC LYMPHOMA KINASE | ONCOLOGY | NEVER-SMOKERS | GROWTH-FACTOR | RECEPTOR TYROSINE KINASE | ACTIVATING MUTATIONS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Molecular Targeted Therapy | Genetic Variation | Young Adult | Pyridines - adverse effects | Drug Interactions | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Lung Neoplasms - genetics | Proto-Oncogene Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | In Situ Hybridization, Fluorescence | Signal Transduction - genetics | Pyrazoles - metabolism | Pyridines - metabolism | Receptor Protein-Tyrosine Kinases - genetics | Gene Rearrangement | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung Neoplasms - diagnosis | Protein-Tyrosine Kinases - antagonists & inhibitors | Academia-Pharma Intersect
Journal Article
Cancer Discovery, ISSN 2159-8274, 08/2015, Volume 5, Issue 8, pp. 850 - 860
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2016, Volume 11, Issue 5, pp. 613 - 638
Journal Article
The Oncologist, ISSN 1083-7159, 06/2016, Volume 21, Issue 6, pp. 762 - 770
Journal Article
Journal Article
Journal Article